SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 235 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is 1.97 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $798,000 | -14.9% | 33,650 | -1.5% | 0.07% | -14.1% |
| Q3 2019 | $938,000 | -17.0% | 34,150 | 0.0% | 0.08% | -15.0% |
| Q2 2019 | $1,130,000 | -8.3% | 34,150 | -2.8% | 0.10% | -7.4% |
| Q1 2019 | $1,232,000 | -1.2% | 35,150 | -6.4% | 0.11% | -12.2% |
| Q4 2018 | $1,247,000 | -33.7% | 37,550 | +0.5% | 0.12% | -18.0% |
| Q3 2018 | $1,881,000 | -15.8% | 37,350 | 0.0% | 0.15% | -20.6% |
| Q2 2018 | $2,235,000 | +18.3% | 37,350 | -9.5% | 0.19% | +27.7% |
| Q1 2018 | $1,889,000 | +10.9% | 41,250 | -3.5% | 0.15% | +16.5% |
| Q4 2017 | $1,704,000 | -0.4% | 42,750 | 0.0% | 0.13% | -4.5% |
| Q3 2017 | $1,710,000 | -5.6% | 42,750 | +1.7% | 0.13% | -8.3% |
| Q2 2017 | $1,812,000 | +38.3% | 42,050 | +0.5% | 0.14% | +39.4% |
| Q1 2017 | $1,310,000 | +22.8% | 41,850 | -0.9% | 0.10% | +28.4% |
| Q4 2016 | $1,067,000 | -5.6% | 42,250 | -7.5% | 0.08% | +12.5% |
| Q3 2016 | $1,130,000 | +7.5% | 45,700 | -11.4% | 0.07% | +60.0% |
| Q2 2016 | $1,051,000 | – | 51,600 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 7,641,250 | $107,207,000 | 7.06% |
| HealthInvest Partners AB | 782,746 | $10,982,000 | 6.50% |
| KOPP INVESTMENT ADVISORS LLC | 729,960 | $10,241,000 | 5.51% |
| Murphy Michael R | 1,028,304 | $14,427,000 | 4.96% |
| Opaleye Management Inc. | 460,000 | $6,454,000 | 3.18% |
| ASHFORD CAPITAL MANAGEMENT INC | 511,244 | $7,173,000 | 1.68% |
| Bruce & Co., Inc. | 394,581 | $5,535,000 | 1.42% |
| AlphaOne Investment Services, LLC | 235,065 | $3,297,000 | 1.40% |
| Ranger Investment Management | 1,560,453 | $21,893,000 | 1.23% |
| NORTHPOINTE CAPITAL LLC | 584,753 | $8,204,000 | 1.07% |